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Abstract 
 
Purpose 
To compare the pharmacokinetics of 13-cis retinoic acid (13-cisRA) between Indian and UK 
neuroblastoma patients receiving comparable treatment, alongside measures of toxicity and 
response.  
Methods 
13-cisRA (160mg/m2/day) was administered to 36 patients ≤16 years in two divided doses. 
Plasma 13-cisRA concentrations were determined on days 1 and 14 of cycles 1 and 4 of 
treatment. Area under the plasma concentration-time curve (AUC0-6h) was estimated using non-
compartment modeling. Patients were genotyped for UGT2B7, CYP3A5*3, CYP3A7*2 and 
*2,*3 and *4 variants of CYP2C8.  
Results 
Marked inter-patient variability in 13-cisRA pharmacokinetics was observed. There was a trend 
towards a higher AUC0-6h on day 1 versus day 14 for both treatment cycles studied. Children who 
swallowed 13-cisRA capsules (n=18) achieved higher AUC0-6h values compared to those who 
could not (n=16) (Mean AUC 21.53 vs. 9.35 µM.h, P<0.05). Patients who were event free at one 
year tended to have higher AUC0-6h on C1D1 compared to those patients who progressed, 
although this did not reach significance with the number of patients studied (P=0.08). Similarly, 
patients who achieved a 13-cisRA Cmax of ≥2 µM on C1D1 tended to have higher median EFS 
compared to those who did not (17.0 vs. 8.1 months). UGT2B7, CYP2C8*2/*3/*4 or CYP3A5*3 
genotype did not have any effect on 13-cisRA pharmacokinetics.   
Conclusions 
Method of administration markedly affects 13-cisRA pharmacokinetics in Indian neuroblastoma 
patients, supporting similar findings in UK patients. An appropriate oral liquid formulation of 
13-cisRA that can be administered to all children with neuroblastoma is urgently needed on an 
international level. 
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Introduction 
The retinol derivative 13-cis retinoic acid (13-cisRA) is now an established component of the 
treatment of high-risk neuroblastoma [1]. Low-dose 13-cisRA previously showed limited clinical 
benefit in patients with recurrent disease. Administration of 13-cisRA at a higher dose of 160 
mg/m2/day and use of an intermittent regimen in a Children’s Cancer Group phase III 
randomized trial showed  significant improvement in 3-year event-free survival (EFS) [2]. Thus, 
dose intensity and corresponding drug exposure in patients treated with 13-cisRA may represent 
important determinants of drug efficacy in this scenario [3]. There is potential for optimizing 
retinoid treatment through adaptive dosing approaches in a neuroblastoma clinical setting, owing 
to the observed large degree of interpatient variability in drug disposition and narrow therapeutic 
window for toxicity versus efficacy [4, 5].  
While 13-cisRA is an established component for treatment of high risk neuroblastoma, its 
administration in pediatric patients may cause altered or reduced exposure in patients who are 
unable to swallow the capsules. This is particularly an issue in a disease such as neuroblastoma 
where the majority of patients being treated are less than 5 years of age. In these patients the 
contents are routinely extracted and mixed with ingestible food or drink, as previously described 
in UK patient populations [1, 5]. 
Retinoids are also known to undergo autoinduction, a phenomenon associated with disease 
relapse in acute promyelocytic leukemia patients treated with all-trans-retinoic acid (ATRA). 
Similar autoinduction has also been described for 13-cisRA which might necessitate an adaptive 
dosing approach in neuroblastoma patients [5, 6]. Drug metabolism studies have shown that 13-
cisRA is a substrate for CYP2C8 and UDP glucuronyltransferase and therefore genetic 
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polymorphisms of genes coding these enzymes may have an effect on the disposition and plasma 
concentration of 13-cisRA [5, 7, 8]. 
The current study was designed to evaluate the pharmacokinetics of 13-cisRA, establish its 
correlation with treatment outcomes and study the impact of certain genetic polymorphisms on 
13-cisRA disposition in an Indian patient population. 
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Materials and Methods 
Patients and setting 
Study protocols were approved by the Institutional Review Board (IRB) and written informed 
consent was obtained from patients and their parents / guardians as appropriate. Patients up to 16 
years of age who were receiving 13-cisRA as part of standard clinical treatment for high-risk 
neuroblastoma at our centre were eligible to participate in the study. The standard treatment 
comprised of induction chemotherapy (cisplatin, carboplatin, vincristine, etoposide and 
cyclophosphamide) followed by surgery, autologous bone marrow transplantation and 
radiotherapy, prior to starting 13-cisRA. Demographic data including age, weight and height 
were recorded for each patient. The baseline Hb, WBC, platelet counts and the most recent ALT, 
serum transaminases, bilirubin and creatinine were documented prior to 13-cisRA treatment. 
Details of 13-cisRA administration and concomitant medications being administered prior to 
and/or in combination with 13-cisRA were recorded. 
Patients with progressive disease after consolidation regimen, those not likely to show 
compliance to the study medication, those who consumed grapefruit or grapefruit products less 
than one week before sample collection for pharmacokinetic analysis or those receiving any 
medication which is a known CYP2C8 enzyme inducer or inhibitor (including omeprazole, 
montelukast, trimethoprim and rifampicin) less than 14 days prior to participation in the study, 
were excluded from the trial. 
Treatment regimen for pediatric patients 
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13-cisRA (Isotroin 10/20mg soft gel capsules, Cipla, India) was administered orally at a dose of 
160 mg/m2/day in two divided doses for 14 days every 28 days for 6 cycles. For patients who 
were unable to swallow 13-cisRA capsules, each capsule was punctured and the contents were 
mixed with water. All patients and/or parents were adequately trained on drug administration, 
especially those who required the capsules to be punctured and administered. The child’s 
parent/guardian would observe the clinical research coordinator (CRC) prepare the morning dose 
of 13-cisRA on day 1 of cycle 1. The evening dose would be prepared and administered by the 
parent/guardian under the CRC’s supervision.  Subsequent doses were administered at home by 
the parent/guardian until the next hospital visit for pharmacokinetic sampling. Administration of 
13-cisRA on the days of pharmacokinetic sampling was performed in hospital under supervision. 
Blood sampling and analysis 
Pharmacokinetic blood samples were collected on day 1 and 14 of cycle 1 and 4 at 0, 1, 2, 4 and 
6 hours after the morning dose. Blood samples (4 ml) were collected in heparinised tubes and 
centrifuged at 1,200 g for 10 min at 4°C. Plasma was separated and frozen at -20°C, before 
analysis using a high performance liquid chromatography (HPLC) assay. All blood and plasma 
samples were stored protected from light and all sample handling was carried out in dim light. 
The assay was validated with regard to linearity, reproducibility and stability of the analytes 
according to bioanalytical method validation guidelines of the FDA [9]. The assay was also cross 
validated against the method employed at Newcastle University, where several large clinical 
trials have been conducted and published [1,5], by analyzing three blinded spiked samples in the 
low, mid and high range of the 13-cisRA linearity curve. 
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A HPLC system consisting of a Dionex UHPLC Ultimate model 3000 (Dionex, USA) connected 
to a UV/Visible absorbance detector (Dionex) was used for sample analysis. Chromatographic 
separations were performed using a reverse-phase HPLC column [C18 (5 μm, 250 × 4.6 mm i.d., 
Merck, USA)]. 13-cisRA was detected by the UV-vis absorbance at 360 nm. The mobile phase 
used was composed of 40% acetonitrile, 17% sodium dihydrogen orthophosphate and 43% 
methanol at a flow rate of 1.7 mL/min. The injection volume was 20 μL and the column was 
maintained at 40°C. 
Toxicity assessment 
Toxicity was assessed in all patients who received at least a single dose of the drug. Adverse 
effects were graded as per the CTCEA version 3.00. All patients underwent routine biochemistry 
tests and blood count assessment before the start of each cycle. Any lab abnormalities were 
documented in addition to any side effects or dose interruptions experienced in the previous 
cycle.  
Pharmacogenetics 
A 3 ml blood was collected in an EDTA tube at the beginning of treatment for pharmacogenetic 
analysis. DNA was extracted from leucocytes using a QIAamp DNA Blood Mini Kit (QIAGEN) 
and quantified using a NanoDrop ND-1000 UV-Vis Spectrophotometer. The frequency of allelic 
variations for *2,*3 and *4 variants of CYP2C8 were investigated by polymerase chain reaction–
restriction fragment length polymorphism (PCR–RFLP) method. After PCR amplification, 5 μl 
of the diluted PCR product (1:10) was digested with appropriate restriction enzymes before 
electrophoresis using 3% agarose gel. Gene polymorphisms for UGT2B7, CYP3A5*3 and 
 
 
9 
 
CYP3A7*2 were assessed using TaqMan® probes. The primers and TaqMan® probes were 
designed by Applied Biosystems (TaqMan® Assays-by-Design, Applied Biosystems). 
Statistical analysis 
Pharmacokinetic parameters including Cmax, AUC, Tmax and half-life were analyzed descriptively 
using WinNonlin version 6.0. 13-cisRA AUC values determined on C1D1 versus C1D14, and in 
patients who swallowed capsules versus those patients where capsules were punctured on C1D1, 
were compared using paired and unpaired t-tests, respectively. The median event free survival 
(EFS) was estimated from Kaplan-Meier plots and survival was compared using the log-rank 
test. Linear regression analysis was performed to assess significant covariates which may affect 
AUC.  
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Results 
Demographic information 
Thirty five children with high risk neuroblastoma including 26 males and 9 females, with a 
median age of 5 years (range 1-13), were enrolled over a four year period between April, 2010 
and May, 2014. A summary of the demographic data of all patients studied is shown in Table 1. 
A flowchart depicting the process of patient screening, enrolment and evaluation is shown in 
Online Resource 1. Eighteen patients were able to swallow the capsules. For sixteen patients, the 
capsules had to be punctured and the contents mixed with a teaspoonful of water for 
administration. 
Pharmacokinetics and Toxicity 
A marked level of inter-patient variability in 13-cisRA pharmacokinetics was observed (CV, 
C1D1 AUC0-6h = 121%). There was a trend towards a higher AUC0-6h on day 1 as compared to 
day 14 in both treatment cycles studied. Pharmacokinetic parameters for all patients are shown in 
Table 2. 13-cisRA clearance (Cl) ranged from 7.68-14.03 L/hr, which is comparable with a mean 
value of 14.4 L/hr reported by Veal et al on day 14 of cycle 1 [5]. The volume of distribution 
(Vd) ranged from 41.8-174.8 L, comparable on all occasions but C1D14 with that reported by 
Veal et al. A notable feature of pharmacokinetics observed in the Indian cohort of patient is the 
extremely high coefficient of variation (>100%) for Cl and Vd, particularly in the first cycle of 
treatment.  Children who were able to swallow the 13-cisRA capsules (n=18) achieved higher 
AUC0-6h values compared to those who could not (n=16), the difference being statistically 
significant (21.53±5.05 vs. 9.35±2.78 µM.h; P<0.05) (Fig. 1). Additional covariates including 
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serum albumin, creatinine, weight, gender and age were not found to have any significant effect 
on exposure to the drug.  
Twenty four out of 36 patients (67%) in Cycle 1, reported Grade 1 toxicity such as vomiting 
(n=2), dryness of skin and mild itching (n=10), chelitis and stomatitis (n=7), and skin lesions 
(n=7). Severe grade 2 chelitis (n=3) and skin lesions (n=3) were also observed in Cycle 1. In 
Cycle 4, 16 out of 19 patients (84%) were affected by Grade 1 toxicity such as vomiting (n=1), 
dryness of skin, peeling and mild itching (n=13), chelitis (n=5) and skin lesions (n=3). Two 
patients reported Grade 2 toxicity such as severe chelitis and peeling of skin all over the body 
associated with itching. Only 1 patient reported Grade 3 toxicity of extensive skin lesions with 
severe itching. It is interesting to note that this patient exhibited the highest AUC and Cmax on all 
courses of treatment studied. However, no clear correlation was observed between drug exposure 
and toxicity. 
Pharmacogenetics 
Pharmacogenetic associations were evaluated in 22 patients, for whom concomitant 
pharmacokinetic data were available. Six SNPs were analyzed in four genes of putative 
relevance for 13-cisRA disposition. None of the patients carried CYP2C8*2/*3/*4 or CYP3A5*3 
variants. Eleven out of 22 children were heterozygous for CYP3A7*2 allele. When these data 
were combined with data for the selected SNPs from 72 patients recruited to the recently 
published UK study [5], no significant association was found between the various genotypes and 
Cmax for C1D14 (Fig. 2).   
Survival Data 
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The median event free survival (EFS) was 8 months. Patients who were event free at one year 
tended to have a higher 13-cisRA AUC0-6h on C1D1 compared to those who progressed or died 
(23.3±8.79 vs. 9.00±3.86µM.h) However, the difference was not statistically significant.  
Patients who achieved a maximum plasma concentration ≥2 µM on C1D1 had a trend towards a 
higher median EFS compared to those who did not (16.98 vs 8.05 months). Similarly this 
difference was not statistically significant(Online Resource 2). 
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Discussion 
Recent data have been published relating to the potential clinical importance of 13-cisRA 
pharmacokinetic variability in neuroblastoma patients, but only in European and US patient 
populations [1, 5, 6]. The current study was designed to address how the published data 
compared to results obtained from an Indian neuroblastoma population. Cross-validation of the 
assays used to analyse clinical samples in India and the UK was carried out to ensure the 
integrity of the data obtained. It was observed that the estimates of clearance and volume of 
distribution were comparable between UK and Indian neuroblastoma populations, except for 
markedly higher variability observed in Indian patients as compared to the UK cohort. In spite of 
the marked variability in pharmacokinetic parameters, none of the known covariates affected 
drug exposure in the linear regression analysis, suggesting that multiple factors govern the 
disposition of 13-cisRA.  
A number of cytochrome P450 (CYP) enzymes have been identified as playing a role in the 
metabolism of 13-cisRA, with CYP2C8 identified as the most important in terms of activity and 
level of expression in the liver [7, 8]. In the Caucasian population, the allele frequencies for 
CYP2C8*3, CYP2C8*4, CYP3A5*3, and UGT2B7*2 were 8.9%, 2.8%, 91.8% and 49.3%, 
respectively [5, 8]. Genetic polymorphisms for CYP2C8*2/*3/*4 or CYP3A5*3 variants were 
not detected in this study. 50% of our patient population were heterozygous for CYP3A7*2 
allele, as opposed to an allele frequency of 6.2% in the Caucasian population, as reported in the 
UK study. Although the occurrence of polymorphisms is variable amongst the populations, no 
significant impact was observed on the metabolism or exposure of 13-cisRA when these data 
were combined. From the current and published findings, it suggests that genetic variation in the 
CYP and UGT genes investigated does not play a significant role in influencing the 
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pharmacokinetics of 13-cisRA in a neuroblastoma patient setting. While a larger study should be 
carried out, taking into account genetic differences that may be prevalent between Caucasian and 
Asian populations, the data presented are supportive of previously published findings in this area 
[5]. 
 
Although the current study involves a relatively limited number of patients, it clearly shows that 
the level of interpatient pharmacokinetic variability previously observed following 13-cisRA 
treatment in UK and US studies is replicated in an Indian patient population. Incidentally, our 
findings suggest a potential association between drug exposure and EFS. However, confirmatory 
studies should be undertaken to validate these findings due to the small number of patients 
studied. 
With a median age of 4 years, route of 13-cisRA dose administration in a neuroblastoma setting 
poses a serious practical challenge as the majority of patients are unable to swallow the capsules. 
This results in lower plasma retinoid concentrations, often below the proposed therapeutic 
threshold of 2 µM [5]. These children are likely to benefit from a higher 13-cisRA dose. The data 
from Veal et al also support similar dose modifications in children who are unable to swallow 
13-cisRA capsules [5]. More importantly, it highlights the need for a paediatric friendly liquid 
formulation of 13-cisRA to achieve optimal levels of the drug in plasma [3]. In a recent review, 
Bauters et al have discussed the practical implications for the administration of 13-cis retinoic 
acid in children [10]. The EMEA also acknowledges the need for an appropriate formulation of 
13-cisRA that is suitable for children, since the large capsules of 13-cisRA are difficult for small 
children to swallow [11]. Our data confirm that this is a global problem and not one relevant only 
to Western patient populations. 
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In addition, the mean AUC of 13-cisRA was approximately 30% lower on day14 of treatment as 
opposed to day 1 in both cycles. This difference however was not statistically significant. While 
this trend might point towards the phenomenon of auto-induction, determination of the 4-oxo-13-
cisRA metabolite concentration in patient samples would have been more conclusive. 
Interestingly, Veal et al reported accumulation of the 4-oxo metabolite between days 1 and 14 of 
treatment but did not observe a corresponding decrease in the plasma concentrations of the 
parent drug [1]. However, both 13-cisRA and its 4-oxo metabolite are reported to be equipotent 
at inhibiting human neuroblastoma cell lines in vitro [12], and therefore the phenomenon of auto-
induction may be less clinically relevant for 13-cisRA.  
To conclude, high inter-patient variability was observed in 13-cisRA pharmacokinetics. Further, 
it could be a candidate for therapeutic drug monitoring practices if the suggested exposure-effect 
relationship is established in a confirmatory trial. Children who cannot swallow capsules risk 
reduced drug exposure which could affect treatment outcomes. These data highlight that 
administration of this drug is a worldwide problem and needs to be addressed. The findings can 
also be contrasted to a drug such as vincristine, where markedly different pharmacokinetics have 
been shown between UK Wilms tumour patients and comparable patients studied in Malawi 
[13]. Clearly therefore it will be challenging to draw conclusions concerning potential 
differences in the clinical pharmacology of a wide spectrum of different anticancer drugs, 
between developing countries and the US and Europe, without conducting well designed studies. 
It is important that such studies include the cross-validation of appropriate assays in order to 
accurately compare data generated in different laboratories and that collaborative 
pharmacogenetic studies are carried out to obtain the patient numbers required for the generation 
of clinically meaningful data. 
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Table 1: Demographic Data 
Age (years) No. of Patients (%) 
<3 
3-5 
6-10 
11-15 
6 (17) 
15 (43) 
10 (29) 
4 (11) 
Sex  
Male 
Female 
26 (74) 
9 (26) 
Weight (kg)  
Median 
Range 
14.75 
 7-47  
BSA (m2)  
Median 
Range 
 0.67 
0.47-1.3 
Method of 13-cisRA  administration:  
Capsules swallowed 
Drug extracted and mixed with food 
18 
16 
Pharmacokinetic data collected  
Cycle 1 day 1 
Cycle 1 day 14 
Cycle 4 day 11 
Cycle 4 day 14 
33 
28 
19 
18 
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Table 2: Pharmacokinetic parameters of 13-cis retinoic acid 
Parameter Course 1 N Mean Std Dev Course 4 N Mean  Std Dev 
AUC  
(µM.h) 
1 33 14.9 18.1 1 19 19.7 18.8 
14 28 10.3 12.2 14  18 13.8 13.6 
VZ_F (L) 
1 33 70.64 85.14 1 19 43.4 2.2 
14 28 174.8 243 14 18 41.8 11.9 
Tmax (hr) 
1 33 3.4 2.0 1 19 3.68 1.63 
14 28 3.07 2.17 14 18 3.2 1.6 
Cmax (µM) 
1 33 4.57 5.10 1 19 5.9 5.4 
14 28 3.57 4.4 14 18 4.2 4.5 
Cl_F 
(L/hr) 
1 33 7.68 7.48 1 19 9.2 11.2 
14 28 11.2 13.04 14 18 14.03 0.52 
 
Abbreviations: AUC, Area under curve; Vd, Volume of distribution; Tmax, Time to achieve 
maximum concentration; Cmax, Maximum concentration; Cl_F, Clearance. 
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Figure Legends: 
Fig. 1 Plasma concentrations of 13-cisRA observed on day 1 of course 1 of treatment in patients 
who swallowed the capsules versus those patients for whom the contents were extracted and 
administered with water. The difference in exposure (AUC) was statistically significant 
(21.53±5.05 vs. 9.35±2.78 µM.h, P<0.05) 
Fig. 2 Combined data from UK and Indian patients showing association between various 
genotypes and 13-cisRA Cmax on C1D14. No statistically significant difference was observed 
between the different genotypes studied (N=94) 
 
Electronic Supplementary Materials 
Online Resource 1: Flowchart showing number of patients screened, enrolled and evaluated for 
pharmacogenetic and pharmacokinetic outcomes 
Online Resource 2: Patients who achieved maximum 13-cisRA plasma concentration >2 µMon 
C1D1 of treatment had higher median EFS compared to those whose Cmax was <2 µM(16.98 vs 
8.05 months, log rank P=0.15) 
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